Lupin is one of the first companies to receive approval for this formulation originally developed by Gilead Sciences, making it eligible for 180 days of shared generic exclusivity in the US market. The product will be manufactured at Lupin’s Nagpur facility in India. Shares of Lupin Ltd ended at ₹2,099.70, up by ₹53.80, or 2.63%, on the BSE.
